A Study in Leukemia Patients With Karonudib

This study is testing a new drug called karonudib in people with blood cancers — including leukemia, lymphoma, multiple myeloma, and high-risk myelodysplastic syndrome — that have returned or are not responding to standard treatment. Karonudib works by targeting a DNA repair mechanism that cancer cells depend on. **You may be eligible if...** - You are between 18 and 75 years old (age range may be extended in some cases) - You have been diagnosed with AML, ALL, DLBCL, Burkitt lymphoma, multiple myeloma, or high-risk MDS according to WHO 2016 criteria (or relapsed/progressive AML or MDS for the expansion cohort) - You have received standard treatments and your cancer has relapsed, progressed, or is refractory with no suitable standard options remaining - You can provide written informed consent **You may NOT be eligible if...** - You still have access to effective standard treatment options - You have not received at least some prior standard of care treatment - You have received more than 70% of your lifetime maximum anthracycline dose (for the expansion cohort only) Talk to your doctor to see if this trial is right for you.